Adquirir conocimientos sobre aspectos fundamentales para mejorar tu tratamiento a pacientes con hematologías no malignas”  

Las enfermedades hematológicas no malignas en niños se suelen describir como anormalidades leves, benignas y con una resolución espontánea en las primeras semanas de vida de los niños. Por eso, es fundamental contar con profesionales que se encuentren capacitados en estos padecimientos y que puedan brindarle la atención que requieren para sanar de la forma adecuada. Asimismo, es de vital importancia que los enfermeros comprendan que la especialización constante les ayudará a desenvolverse de mejor manera en un área de trabajo que continúa en constante cambio e innovación.

Por eso, la Postgraduate diploma en Nursing Care of the Pediatric Patient with Non-malignant Hematologic Pathology brinda toda la información necesaria y actualizada en este campo. En un primer módulo se les presentarán a los estudiantes las bases de la hematología neonatal y pediátrica, donde explorarán los fundamentos biológicos de las enfermedades en sangre en fetos y neonatos. Por otra parte, contrastarán el desarrollo normal y anormal de niños y adolescentes para el desarrollo de una visión holística de las enfermedades. 

Avanzando en las clases, se conocerán los distintos trastornos en la sangre, como la anemia y sus distintas variantes. El futuro egresado también tendrá la posibilidad de conocer los diferentes trastornos hemorrágicos en recién nacidos y todas las características clínicas y etiológicas que las acompañan. Casi para terminar, se le presentará el Modelo de Cuidados Centrados en el Desarrollo y la Familia, que le ayudará a capacitarse para no solo tratar al paciente, sino brindarle apoyo a los familiares que viven también estas enfermedades.  

El equipo docente reunido para esta Postgraduate diploma es de reconocido prestigio y dispone de una amplia experiencia en unidades de referencia a nivel nacional e internacional en el tratamiento y cuidados de los recién nacidos, niños y adolescentes con enfermedad hematológica. Se cuenta con un programa 100% online que aporta al alumno la facilidad de poder cursarlo cómodamente, dónde y cuándo quiera. Solo necesitará un dispositivo con acceso a internet para lanzar su carrera un paso más allá. Una modalidad acorde al tiempo actual con todas las garantías para posicionar al ingeniero en un sector altamente demandado. 

Conocer los fundamentos de la hemostasia, sus mecanismos de control y las pruebas de laboratorio necesarias para su estudio” 

Esta Postgraduate diploma en Nursing Care of the Pediatric Patient with Non-malignant Hematologic Pathology contiene el programa educativo más completo y actualizado del mercado. Las características más destacadas son:

• El desarrollo de casos prácticos presentados por expertos en Hematología Pediátrica para Enfermería
• Los contenidos gráficos, esquemáticos y eminentemente prácticos con los que está concebido recogen una información científica y práctica sobre aquellas disciplinas indispensables para el ejercicio profesional
• Los ejercicios prácticos donde realizar el proceso de autoevaluación para mejorar el aprendizaje
• Su especial hincapié en metodologías innovadoras
• Las lecciones teóricas, preguntas al experto, foros de discusión de temas controvertidos y trabajos de reflexión individual
• La disponibilidad de acceso a los contenidos desde cualquier dispositivo fijo o portátil con conexión a internet

Aborda las diferentes enfermedades hematológicas en recién nacidos, niños y adolescentes y potencia tu perfil profesional” 

El programa incluye en su cuadro docente a profesionales del sector que vierten en esta capacitación la experiencia de su trabajo, además de reconocidos especialistas de sociedades de referencia y universidades de prestigio.   

Su contenido multimedia, elaborado con la última tecnología educativa, permitirá al profesional un aprendizaje situado y contextual, es decir, un entorno simulado que proporcionará una capacitación inmersiva programada para entrenarse ante situaciones reales.   

El diseño de este programa se centra en el Aprendizaje Basado en Problemas, mediante el cual el profesional deberá tratar de resolver las distintas situaciones de práctica profesional que se le planteen a lo largo del programa. Para ello, contará con la ayuda de un novedoso sistema de vídeo interactivo realizado por reconocidos expertos. 

Aprende los modelos Centrados en el Desarrollo y la Familia para brindar un cuidado centrado en las necesidades individuales y familiares del paciente"

Adquiere los conocimientos sobre aspectos fundamentales de los procedimientos diagnósticos y de seguimiento en el recién nacido con un programa 100% online"

Ensure that students meet the requirements of nursing applied to pediatric patients with non-malignant hematological conditions, a syllabus has been developed whose modules offer a broad perspective of this field of action, allowing the student to describe and update the different treatment modalities most frequently used to address hematological problems in the newborn. From module 1, students will see their knowledge broadened, which will enable them to develop professionally, knowing that they can count on the support of a team of experts. 

Differentiate the multiple types of coagulation and hemostasis disorders in pediatrics, following the most updated program on the market" 

Module 1. Basis of neonatal and pediatric hematology

1.1. Fetal Hematopoiesis

1.1.1. Introduction Prenatal Hematopoiesis
1.1.2. Mesoblastic or Megaloblastic Hematopoiesis
1.1.3. Hepatic Phase
1.1.4. Splenic Phase
1.1.5. Medullary or Myeloid Phase

1.2. Healthy Newborn

1.2.1. Fetal Development
1.2.2. Changes at Birth
1.2.3. First Month of Life

1.3. Postnatal Hematopoiesis

1.3.1. General Concepts Postnatal Hematopoiesis
1.3.2. Types of Hematopoietic Tissue

1.3.2.1. Myeloid Tissue
1.3.2.2. Lymphoid Tissue

1.3.3. Temperature Regulation Stimulation and Inhibition
1.3.4. Erythropoiesis

1.3.4.1. Hemoglobin Synthesis
1.3.4.2. Hemoglobin Alterations

1.3.5. Granulocytopoiesis
1.3.6. Monocytopoiesis
1.3.7. Platelet Formation 

1.4. Composition of the Blood: Formed Elements

1.4.1. Introduction to Blood Cells and Plasma
1.4.2. Blood Functions
1.4.3. Blood Components 

1.4.3.1. Plasma
1.4.3.2. Formal Elements

1.4.3.2.1. Red Cells or Erythrocytes
1.4.3.2.2. Leukocytes

1.4.3.2.2.1. Granular (Neutrophils, Eosinophils, Basophils)
1.4.3.2.2.2. Non-Granular (Lymphocytes, Monocytes)

1.5. Composition of the Blood: Blood Plasma

1.5.1. Blood Plasma Composition

1.5.1.1. Plasma Proteins

1.5.1.1.1. Albumins
1.5.1.1.2. Globulins
1.5.1.1.3. Fibrinogen
1.5.1.1.4. Others

1.5.2. Plasma Functions
1.5.3. Differences between Plasma and Serum

1.6. Blood Groups

1.6.1. Introduction
1.6.2. Antigen Group 0-A-B

1.6.2.1. A and B Antigens: Agglutinogens
1.6.2.2. Genetic Determination of Agglutinogens
1.6.2.3. Aglutinin
1.6.2.4. Agglutination Process in Transfusion Reactions
1.6.2.5. Blood Typing

1.6.3. Rh Blood Type

1.6.3.1. Rh Antigens
1.6.3.2. Rh Immune Response
1.6.3.3. Erythroblastosis Fetalis ("Hemolytic Disease of the Newborn")

1.7. Immune System

1.7.1. General Concepts of Immunology
1.7.2. Immunological System Functions
1.7.3. Immune System Organs

1.7.3.1. Skin and Mucous Membranes
1.7.3.2. Thymus
1.7.3.3. Liver and Bone Marrow
1.7.3.4. Bladder
1.7.3.5. Lymph Nodes

1.7.4. The Innate or Nonspecific System
1.7.5. The Adaptive or Specific System
1.7.6. Humoral Elements in the Immune Response 

1.7.6.1. T Lymphocytes
1.7.6.2. Natural Killer Cells(NK)
1.7.6.3. Antigen-Presenting Cells (HLA Antigen, Macrophages, Dendritic Cells, B Lymphocytes)
1.7.6.4. Polymorphonuclear Cells: Neutrophils, Basophils and Eosinophils

1.8. Fundamentals of Hemostasis

1.8.1. Introduction
1.8.2. Primary Hemostasis

1.8.2.1. Vessels, Endothelium and Platelets
1.8.2.2. Physiology

1.8.2.2.1. Initiation (Platelet Adhesion)
1.8.2.2.2. Extension (Platelet Activation)
1.8.2.2.3. Perpetuation (Platelet Aggregation and Procoagulant Activity)

1.8.3. Secondary Hemostasis or Coagulation

1.8.3.1. Coagulation Factors
1.8.3.2. Physiology

1.8.3.2.1. Extrinsic Pathway
1.8.3.2.2. Intrinsic Pathway

1.8.4. Control Mechanisms of the Coagulation Process
1.8.5. Clot Removal and Fibrinolysis
1.8.6. Laboratory Tests

1.8.6.1. Evaluate Primary Hemostasis
1.8.6.2. Evaluate Coagulation

1.9. Healthy Child

1.9.1. Infant: 1- 24- months
1.9.2. Pre-school Stage
1.9.3. School Stage

1.10. Adolescent Stage 
1.11. Introduction to Hematologic Diseases in Pediatrics

1.11.1. Introduction
1.11.2. Non-Malignant Hematologic Pathologies

1.11.2.1. In Newborns

1.11.2.1.1. Specificities
1.11.2.1.2. Most Frequent Hematologic Pathologies

1.11.2.1.2.1. Non-Physiologic Neonatal Jaundice
1.11.2.1.2.2. Preterm Anemia
1.11.2.1.2.3. Other Anemias of the Newborn
1.11.2.1.2.4. Hemorrhagic Disorders
1.11.2.1.2.5. Polycythemia
1.11.2.1.2.6. Neonatal Shock

1.11.2.2. In Children

1.11.2.2.1. Specificities
1.11.2.2.2. Most Common Pathologies

1.11.2.2.2.1. Anaemia in Pediatrics
1.11.2.2.2.2. Haemoglobinopathies
1.11.2.2.2.3. Coagulation and Hemostasis Abnormalities
1.11.2.2.2.4. Non-Malignant Granulocyte Diseases
1.11.2.2.2.5. Primary Immunodeficiencies
1.11.2.2.2.6. Congenital Spinal Insufficiencies
1.11.2.2.2.7. Most Frequent Infections

1.11.3. Malignant Hematologic Pathologies

1.11.3.1. Leukaemias
1.11.3.2. Lymphomas

1.11.3.2.1. Hodgkin's Lymphomas
1.11.3.2.2. Non-Hodgkin's Lymphoma

Module 2. Non-malignant hematologic pathology in newborns

2.1. Hematologic Reference Values in Newborns

2.1.1. Introduction
2.1.2. Reference Values in the Hemogram of the Newborn at term

2.1.2.1. Reference Values of the Red Series in the RNAT
2.1.2.2. Reference Values of the White Series in the RNAT

2.1.3. Reference Values in RNAT Biochemistry
2.1.4. Reference Values in RNAT Hemostasis
2.1.5. Reference Values in the RNAT Blood Gas Measurement

2.1.5.1. Blood Gasometry at Birth
2.1.5.2. Gasometry at 24 Hours of Life 

2.2. Nonphysiologic Neonatal Jaundice and Hemolytic Disease of the Newborn

2.2.1. Introduction
2.2.2. Basic Pathogenic Concepts
2.2.3. Aetiopathogenesis.

2.2.3.1. Physiological Jaundice
2.2.3.2. Non-Physiologic jaundice
2.2.3.3. Jaundice due to Rh Factor Incompatibility

2.2.3.3.1. Hemolytic Disease of the Newborn

2.2.4. Clinical Complications

2.2.4.1. Acute Bilirubin Encephalopathy
2.2.4.2. Chronic Encephalopathy or Kernicterus

2.2.5. Diagnosis of the Newborn with Jaundice

2.2.5.1. Medical history
2.2.5.2. Physical Exploration
2.2.5.3. Laboratory Tests

2.2.6. Treatment

2.2.6.1. Phototherapy
2.2.6.2. Exchange Transfusion
2.2.6.3. Pharmacological Therapy

2.3. Preterm Anemia

2.3.1. Definition of Anemia of Prematurity (AOP)

2.3.1.1. Anemia Considerations in the Preterm Newborn (PTNB)
2.3.1.2. Features of a RNPT
2.3.1.3. Hematological Characteristics of PTNB

2.3.2. Classification of Anemia by Weeks of Gestation and Corrected Weeks of Gestation
2.3.3. Epidemiology of Anemias in the Newborn Pediatric  Anemias
2.3.4. Pathophysiology and Most Common Causes of Anemia in Preterm Preemies

2.3.4.1. Anemias Related to Decreased Erythrocyte Production
2.3.4.2. Anemias Related to Increased Erythrocyte Destruction
2.3.4.3. Anemias Related to Total Blood Volume Loss

2.3.5.Clinical symptoms

2.3.5.1. Generalities
2.3.5.2. Related to the Cause
2.3.5.3. Gestational Age Related

2.3.6. Diagnosis

2.3.6.1. Prenatal Diagnosis. Is It Possible?
2.3.6.2. Differential Diagnosis
2.3.6.3. Complementary Tests

2.3.6.3.1. General aspects
2.3.6.3.2. How to Perform a Hemogram Correctly in a PTNB?

2.3.7. Treatment

2.3.7.1. Transfusion Treatment
2.3.7.2. Other Treatments of the Cause

2.3.7.2.1. Erythropoietin Administration
2.3.7.2.2. Autotransfusions

2.3.8. Evolution and Prognosis of Anemias in the PTNB

2.4. Other Anemias of the Newborn and Infant

2.4.1.Difference between Physiological and Non-Physiological Anemia
2.4.2.Most Important Pathophysiological Differences between PTNB and Term Newborns (TNB)
2.4.3.Causes of Anemias in Newborns and Infants

2.4.3.1. Hemorrhagic
2.4.3.2. Hemolytics
2.4.3.3. Hypoplastic

2.4.4.Characteristics of Hypoplastic Anemias

2.4.4.1. Physiological Hypoplastic Anemia
2.4.4.2. Congenital Hypoplastic Anemia

2.4.4.2.1. Diamond-Blackfan
2.4.4.2.2. Fanconi Anemia
2.4.4.2.3. Dyserythropoietics
2.4.4.2.4. Idiopathic Aplasia
2.4.4.2.5. Estren-Dameshek

2.4.4.3. Secondary Aplastic Anemia

2.4.4.3.1. Congenital Leukemia
2.4.4.3.2. Infections
2.4.4.3.3. Post-Transfusion Anemias
2.4.4.3.4. Others

2.4.5. Secondary Aplastic Anemia
2.4.6. Differential Diagnosis and Complementary Tests
2.4.7. Transfusion Treatments and Criteria According to Age (RNAT/Infant)
2.4.8. Other Treatments: Exchange Transfusion
2.4.9.  Treatment Considerations. New Treatments

2.5. Hemorrhagic Disorders in Newborns

2.5.1. Introduction
2.5.2. Clinical symptoms
2.5.3. Etiology of Hemorrhagic Disorders in the Neonate

2.5.3.1. Acquired Causes

2.5.3.1.1. Vitamin K Deficiency
2.5.3.1.2. Disseminated Intravascular Coagulation (DIC)
2.5.3.1.3. Hepatopathies
2.5.3.1.4. Extracorporeal Membrane Oxygenation (ECMO)
2.5.3.1.5. Others: α2 Antiplasmin Deficiency, Vascular Problems, Obstetric Trauma, Platelet Qualitative Disorders, Acquired Immune and Non-immune Thrombopenias.

2.5.3.2. Hereditary Causes

2.5.3.2.1. Congenital Deficiency of Clotting Factors: Hemophilia, Von Willebrand's Disease

2.5.4. Diagnosis of the Newborn with Hemorrhage

2.5.4.1. Medical history
2.5.4.2. Physical Exploration
2.5.4.3. Laboratory Tests

2.5.5. Treatment of Hemorrhage in Newborns

2.6. Polycythemia in the Newborn

2.6.1. Introduction
2.6.2. Aetiopathogenesis

2.6.2.1. Blood Transfusion (Hypervolemia)
2.6.2.2. Increased Erythropoyesis (Normovolemia)
2.6.2.3. Hemoconcentration Due to Volume Depletion
2.6.2.4. Others: Physiological, Beckwith-Wiedemann Syndrome, Beckwith-Wiedemann Syndrome

2.6.3. Clinical symptoms

2.6.3.1. Neurological Manifestations
2.6.3.2. Hematological Manifestations
2.6.3.3. Cardiac Manifestations
2.6.3.4. Respiratory Manifestations
2.6.3.5. Gastrointestinal Manifestations
2.6.3.6. Renal and Genitourinary Manifestations
2.6.3.7. Dermatological Manifestations
2.6.3.8. Metabolic Manifestations

2.6.4. Diagnosis
2.6.5. Treatment of Polycythemia in the Newborn

2.6.5.1. General Measures
2.6.5.2. Partial Exchange Transfusion

2.6.6. Prognosis

2.7. Thrombocytopenias in Newborns

2.7.1. Introduction
2.7.2. Clinical symptoms
2.7.3. Etiology

2.7.3.1. Acquired Thrombocytopenias

2.7.3.1.1. Diseases: Hepatopathies, Intraventricular Hemorrhage, Intraventricular Hemorrhage
2.7.3.1.2. Ictericia Severa

2.7.3.2. Hereditary Thrombocytopenias

2.7.3.2.1. Autosomal Recessive: Glanzmann Thrombasthenia, Bernard-Soulier Syndrome.
2.7.3.2.2. Autosomal Dominant: Platelet-Type Von Willebrand's Disease, Quebec Platelet Syndrome

2.7.4. Classification According to the Type of Thrombocytopenia

2.7.4.1. Immune Neonatal Thrombocytopenia: Alloimmune or Autoimmune
2.7.4.2. Infectious Neonatal Thrombocytopenia
2.7.4.3. Neonatal Thrombocytopenia of Genetic Origin
2.7.4.4. Various Causes

2.7.5. Diagnosis of the Newborn with Hemorrhage

2.7.5.1. Medical history
2.7.5.2. Physical Exploration
2.7.5.3. Laboratory Tests

2.7.6. Treatment of Thrombocytopenia in Newborns

2.8. Neonatal Shock

2.8.1. Introduction

2.8.1.1. Pathophysiological Bases
2.8.1.2. Types of Shock
2.8.1.3. Risk Factors Associated with Neonatal Shock

2.8.2. Etiology of Neonatal Shock
2.8.3. Neonatal Shock Clinic
2.8.4. Diagnosis of Neonatal Shock

2.8.4.1. Medical history
2.8.4.2. Physical Exploration
2.8.4.3. Complementary Tests

2.8.5. Treatment of Neonatal Shock 

Module 3. Specificities of care in neonates with non-malignant hematologic pathology 

3.1. Developmental and Family Centered Care Model. NIDCAP

3.1.1. Introduction to the Model
3.1.2. Synactive Theory
3.1.3. Neurodevelopment and Behaviors of Newborns
3.1.4. The Family as Primary Caregiver
3.1.5. Teamwork

3.2. Application of NIDCAP in Newborns

3.2.1. Positioning and Manipulation
3.2.2. Babysitting Method
3.2.3. Painful Procedures
3.2.4. Inclusion of the Family in Care

3.3. Adaptation of the Neonatal Unit According to the NIDCAP Model

3.3.1. Lighting and Acoustic Control
3.3.2. Doors Open 24 Hours a Day
3.3.3. Grouping of Procedures and Manipulations
3.3.4. Sibling Project
3.3.5. Joint Hospitalization
3.3.6. "At Home with You"

3.4. The Importance of Feeding and Nutrition in the Neonate

3.4.1. Feeding of the Neonate with Nonmalignant Hematologic Pathology
3.4.2. Breastfeeding
3.4.3. Breast Milk Bank
3.4.4. Artificial Breastfeeding

3.5. Diagnostic and Follow-up Procedures in The Newborn

3.5.1. Anamnesis and Detailed Examination
3.5.2. Blood Group and Coombs Test
3.5.3. Blood Analysis
3.5.4. Transcutaneous Bilirubin
3.5.5. Food Control and Elimination
3.5.6. Other Procedures

3.6. Venous Access in the Neonate

3.6.1. Umbilical Venous Catheter (CVU)
3.6.2. Epicutaneocava Catheter
3.6.3. Tunneled Central Venous Catheter type broviac
3.6.4. Central Femoral and Jugular Venous Lines
3.6.5. Peripherally Inserted Central Venous Catheter (PICC)
3.6.6. Peripheral Venous Line

3.7. Most Frequent Treatments in the Neonate with Hematologic Pathology

3.7.1. Hemorrhagic Disease Prophylaxis
3.7.2. Phototherapy
3.7.3. Intravenous Immunoglobulins
3.7.4. Seroalbumin
3.7.5. Exchange Transfusion
3.7.6. Complementary Treatments
3.7.7 Metalloporphyrins

3.8. Specific Nursing Care in the Management of the Infant with Nonphysiologic Neonatal Jaundice

3.8.1. Theoretical Framework

3.8.1.1. Nursing Care Based on the Virginia Henderson Model

3.8.2. Nursing Care of Newborns with Nonphysiologic Neonatal Jaundice

3.8.2.1. Nursing Care Relating to Phototherapy
3.8.2.2. Nursing Care Relating to Exchange Transfusion
3.8.2.3. Nursing Care Relating to Pharmacological Treatment

3.8.3. Phases of the Nursing Process

3.8.3.1. Evaluation
3.8.3.2. Detection of Problems. Diagnosis
3.8.3.3. NOC Planning
3.8.3.4. Execution NIC
3.8.3.5. Assessment

Module 4. Non-malignant hematologic pathology in children 

4.1. Anaemia in Pediatrics(I)

4.1.1. Introduction. Concepts
4.1.2. General Pathophysiology of Anemias in Pediatrics
4.1.3. Classification of Anemias

4.1.3.1. Morfoligical
4.1.3.2. Pathophysiological
4.1.3.3. By Establishment

4.1.4. Prevalence and Incidence of Anemias in Pediatrics
4.1.5. General Signs and Symptoms
4.1.6. Differential Diagnosis According to Type of Anemia
4.1.7. Iron Deficiency Anemia

4.2. Anemias in Pediatrics (II)

4.2.1. Microcytic Anemia

4.2.1.1. Ferropénica
4.2.1.2. Thalassemia
4.2.1.3. Chronic Inflammatory Disease
4.2.1.4. Others

4.2.1.4.1. Copper Deficiency Anemia
4.2.1.4.2. Anemia Due to Intoxication
4.2.1.4.3. Others

4.2.2. Normocytic Anemia

4.2.2.1. Definition and Possible Causes

4.2.2.1.1. Bone Marrow Aplasia/Hypoplasia
4.2.2.1.2. Hemophagocytic Syndrome

4.2.3. Macrocytic Anemia

4.2.3.1. Vitamin B12 Deficiency Anemia
4.2.3.2. Folate Deficiency Anemia
4.2.3.3. Lesch-Nyhan Syndrome
4.2.3.4. Bone Marrow Failure

4.2.4. Hemolytic Disorders

4.2.4.1. Haemoglobinopathies
4.2.4.2. Enzymopathies
4.2.4.3. Immune Hemolytic Anemia
4.2.4.4. Extrinsic Factors

4.2.4.4.1. Wilson's disease
4.2.4.4.2. Hemolytic Uremic Syndrome
4.2.4.4.3. Thrombotic Thrombocytopenic Purpura
4.2.4.4.4. Disseminated Intravascular Coagulation

4.3. Hemoglobinopathies: Sickle Cell Disease and Thalassemias

4.3.1. Quantitative Hemoglobinopathies: Thalassemias

4.3.1.1. Definition
4.3.1.2. Pathophysiology
4.3.1.3. Thalassemia Major or Cooley's Clinic
4.3.1.4. Treatment

4.3.1.4.1. Hypertransfusion and Iron Chelators
4.3.1.4.2 .Allogeneic HSCT

4.3.2. Qualitative Hemoglobinopathies: Sickle Cell Disease

4.3.2.1. Definition
4.3.2.2. Clinical symptoms

4.3.2.2.1. Hemolytic Anemia, Vasculopathy and Chronic Organ Damage
4.3.2.2.2. Venoocclusive Crises
4.3.2.2.3. Infections
4.3.2.2.4. Others

4.3.2.3. Treatment

4.3.2.3.1. Pain
4.3.2.3.2. Emergency
4.3.2.3.3. Surgical Interventions
4.3.2.3.4. Allogeneic HSCT

4.4. Alterations of Coagulation and Hemostasis in Pediatrics

4.4.1. Thrombocytopenias

4.4.1.1. Concept
4.4.1.2. Primary Immune Thrombocytopenia (PID)

4.4.1.2.1. Definition
4.4.1.2.2. Etiology
4.4.1.2.3. Clinical symptoms
4.4.1.2.4. Treatment

4.4.1.2.4.1. Intravenous Corticosteroids and Immunoglobulins
4.4.1.2.4.2. IG Anti-D, Chrysotherapy
4.4.1.2.4.3. Splenectomy, Thrombopoietin Eeceptor Agonists, Rituximab
4.4.1.2.4.4. According to Acute or Chronic

4.4.2. Hemophilia A and B

4.4.2.1. Etiology
4.4.2.2. Clinical symptoms
4.4.2.3. Treatment

4.4.2.3.1. Inactivated or Recombinant Plasma Concentrate
4.4.2.3.2. Desmopressin
4.4.2.3.3. Vaccination and Sport Specificities

4.4.3. Von Willebrand Disease (VWD)

4.4.3.1. Definition
4.4.3.2. Etiology
4.4.3.3. Clinical symptoms
4.4.3.4. Treatment

4.5. Non-Malignant Granulocyte Diseases

4.5.1. Neutropenia

4.5.1.1. Classification
4.5.1.2. Severe Congenital Neutropenia

4.5.1.2.1. Signs and Symptoms
4.5.1.2.2. Epidemiology
4.5.1.2.3. Diagnosis
4.5.1.2.4. Treatment
4.5.1.2.5. Complications

4.5.2. Congenital Defects of Phagocytic Function

4.5.2.1. Clinical Characteristics
4.5.2.2. Prevalence
4.5.2.3. Genetic Diagnosis and Advice
4.5.2.4. Treatment

4.6. Primary Immunodeficiencies

4.6.1. Introduction to Primary Immunodeficiencies (PID)
4.6.2. PID Clinic
4.6.3. Diagnosis of PIDs
4.6.4. Types of IDP
4.6.5. Treatment of PIDs

4.7. Congenital Spinal Insufficiencies(IMC)

4.7.1. Concept
4.7.2. Classification

4.7.2.1. Global BMI

4.7.2.1.1. Definition
4.7.2.1.2. Fanconi Anemia
4.7.2.1.3. Síndrome de Shwachman-Diamond

4.7.2.1.3.1. Introduction
4.7.2.1.3.2. Clinical symptoms
4.7.2.1.3.3. Treatment

4.7.2.2. IMC aisladas

4.7.2.2.1. Blackfan-Diamond Anemia

4.7.2.2.1.1. Definition
4.7.2.2.1.2. Clinical symptoms
4.7.2.2.1.3. Treatment

4.8. Congenital Medullary Insufficiencies: Fanconi's Anemia

4.8.1. Definition
4.8.2. Differentiation between Fanconi Anemia and Fanconi Syndrome
4.8.3. Characteristics of Fanconi Anemia
4.8.4. Diagnosis

4.8.4.1. Diagnostic suspicion

4.8.4.1.1. For Brother Diagnosed with Fanconi's Anemia
4.8.4.1.2. Due to the Appearance of Aplastic Anemia or Bone Marrow Failure
4.8.4.1.3. For the Appearance of Myelodysplasia or Leukemia

4.8.4.2. Tests

4.8.4.2.1. Prenatal Diagnosis
4.8.4.2.2. Ultrasound
4.8.4.2.3. Flow Cytometry Analysis
4.8.4.2.4. Blood Count
4.8.4.2.5. Bone Marrow Aspirate (BMA) and Bone Marrow Biopsy
4.8.4.2.6. Others

4.8.5. Treatment

4.8.5.1. Support

4.8.5.1.1. Androgen Derivatives
4.8.5.1.2. Growth Factors
4.8.5.1.3. Blood Transfusions

4.8.5.2. Curative

4.8.5.2.1. Allogeneic Hematopoietic Progenitor Transplantation
4.8.5.2.2. Genetic Therapy
4.8.6. Prognosis

4.9. Most Frequent Infections in Pediatric Patient with Hematologic Pathology

4.9.1. Factors Predisposing to Infection
4.9.2. Infection Prevention
4.9.3. Most Frequent Infections

4.9.3.1. Febrile Neutropenia
4.9.3.2. Bacteremia
4.9.3.3. Sepsis and Septic Shock
4.9.3.4. Respiratory Infections
4.9.3.5. Digestive Infections
4.9.3.6. CNS Infections
4.9.3.7. Infections by Multiresistant Organisms
4.9.3.8. Viral Infections

Develop your skills by taking a program that will allow you to broaden your holistic, tolerant and sensitive view of pediatric patients with hematological diseases"